Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Mylan (MYL) Shares Look to Stabilize After Pounding on 'Desparate' Meda Deal
February 11, 2016 11:09 AM ESTMylan (NASDAQ: MYL) is attempting to stabilize as investors express disappointment with the Meda deal, sending the stock in free-fall. Analysts called the deal,... More
Mylan (MYL) Miss Overshadowed by Mediocre Deal - Guggenheim
February 11, 2016 8:07 AM ESTAfter the 4Q15 miss and announcement of the deal to acquire Meda Guggenheim analyst, Louise Chen, remains on the sidelines and kept her Neutral rating on Mylan (NASDAQ: MYL) shares. This acquisition makes strategic sense, but Meda (3% topline, 5% EBITDA growth) does not enhance MYL's sales and earnings profile. This is important ahead of potential generic competition for Epipen in 2H16. No change to... More
RBC Capital Views Mylan's (MYL) Meda Purchase as Desperate - PT to $58
February 11, 2016 8:05 AM ESTRBC Capital reiterated a Sector Perform rating on Mylan (NASDAQ: MYL), and cut the price target to $58.00 (from $60.00), following the company's announcement that they will acquire Meda for $9.9 billion. Separately, MYL missed 4Q. Neither will help the stock and this deal feels desperate in RBC's... More
Mylan (MYL) Misses Q4 EPS by 5c
February 10, 2016 4:13 PM ESTMylan (NASDAQ: MYL) reported Q4 EPS of $1.22, $0.05 worse than the analyst estimate of $1.27. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.7 billion.
GUIDANCE:
Mylan sees FY2016 EPS of $4.85-$5.15, versus the consensus of $4.90.
For earnings history and earnings-related data on Mylan (MYL) click here.
... More